LRCH4

Across TCGA pan-cancer cohorts, LRCH4 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated LRCH4 data layer compared with 22 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher LRCH4 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated LRCH4 expression acts as an unfavorable survival marker, although some lineages such as LUAD and UCEC show a favorable association.

LUAD, PDAC, and UCEC are the cancer types where LRCH4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	All	0.765	0.348	<.001	38	view →
PDAC	DFS	Tertile	III,IV	0.449	1.000	.001	18	view →
UCEC	DFS	Tertile	All	0.968	0.875	.030	12	view →
HNSC	DFS	Tertile	All	0.966	0.496	.040	8	view →
GBM	DFS	Quartile	All	0.551	0.817	.009	8	view →
LSCC	DFS	Median	All	0.913	0.956	.031	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

LRCH4–LUAD (DFS)

Open the LUAD breakdown →